Cross-Sector entity
All 1 tracked stories fall under one category: pharma. Fidelity National is most often covered alongside Amtagvi, which appears in 1 of these 1 story. The tracked stories average 2 original sources each. Fidelity National appears in 1 tracked Cross-Sector story from February 23, 2026.
1 verified story tracked
Last mentioned: Feb 23, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
All 1 tracked stories fall under one category: pharma. Fidelity National is most often covered alongside Amtagvi, which appears in 1 of these 1 story. The tracked stories average 2 original sources each. Fidelity National appears in 1 tracked Cross-Sector story from February 23, 2026.
Computed from the 1 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Fidelity National. Shared-story counts are live from our verified record — not editorial picks.
Iovance Biotherapeutics is set to report Q4 2025 results, marking a full year of commercial operations for its breakthrough TIL therapy, Amtagvi. The update will be a critical indicator of the company's ability to scale complex cell therapy logistics and expand its market presence in oncology.
